A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma

Inclusion Criteria: * Histopathologically confirmed glioblastoma (astrocytoma WHO grade IV) * MGMT promoter methylation status is negative * Brain MRI confirmation of disease according to RANO (Response Assessment in Neuro-Oncology) criteria * Completion of standard-of-care temozolomide-based chemoradiation for post-operative treatment of glioblastoma plus two-to-six week "washout" period and stable-to-improved baseline brain MRI. * Male and female subjects between the ages of 18 and 85 years * Karnofsky Performance Score ≥ 60% * Expected survival of at least six months from the day of enrollment * No severe dysfunction of major organs (e.g., bone marrow, liver, kidneys, heart, lungs, etc.) and laboratory results from up to 14 days prior to enrollment fall within criteria: * Hemoglobin \> 10 g/dL * Leukocytes ≥ 3,000 per μl * Absolute neutrophil count ≥ 1,500 per μl * Platelet count \> 100,000 per μl * BUN \< 25 mg * Serum creatinine within normal institutional limits OR Creatinine clearance ≥ 60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal * Total serum bilirubin within normal institutional limits * ALT (SGPT) ≤ 2.5× the institutional upper limit of normal OR AST (SGOT) ≤ 2.5× the institutional upper limit of normal * Ability to take medication sublingually * Willingness and ability to comply with scheduled visits, laboratory tests, and other trial procedures * Accessible for treatment and follow-up * Female subjects: Use of…